Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Merck secures worldwide rights to vernakalant i.v.

Merck, known as MSD outside the United States and Canada, and Astellas US LLC, the U.S. subsidiary of Astellas Pharma Inc. today announced that they have entered into an agreement under which Merck, through a subsidiary, will acquire the exclusive rights to develop and commercialize the investigational intravenous formulation of vernakalant (vernakalant i.v.) in Canada, Mexico and the United States from Astellas.

27 Jul 2011

Special panel votes in favor of HDE approval for EXCOR Pediatric VAD

At the request of Dr. Bram Zuckerman, Director, Division of Cardiovascular Devices, Center for Devices and Radiologic Health of the United States Food and Drug Administration, a special panel was convened on Thursday July 21 in Gaithersburg, Maryland to review the results of the EXCOR® IDE clinical trial.

27 Jul 2011

Health Canada issues notice of compliance for OCPI's SAMSCA to treat hyponatremia

Otsuka Canada Pharmaceutical Inc. (OCPI) announced today that Health Canada has issued a notice of compliance for SAMSCA (tolvaptan), the first medicine approved in Canada for the treatment of hyponatremia.

27 Jul 2011

Hormone therapy may be hazardous in men with pre-existing heart conditions

Adding hormone therapy to radiation therapy has been proven in randomized clinical trials to improve overall survival for men with intermediate- and high-risk prostate cancer. However, adding hormone therapy may reduce overall survival in men with pre-existing heart conditions, even if they have high-risk prostate cancer according to a new study just published online in advance of print in the International Journal of Radiation Oncology·Biology·Physics, the official scientific journal of ASTRO.

26 Jul 2011

Volunteers needed in worldwide study to help people breathe easier

Australian sufferers of chronic obstructive pulmonary disorder (COPD), one of the most important causes of breathlessness and difficulty performing tasks of normal daily life, have the opportunity to participate in a worldwide study, starting this month, assessing a potential new treatment.

26 Jul 2011

Key risk factors for death, transplantation in children with dilated cardiomyopathy

Researchers have identified important risk factors for death and transplantation in children with dilated cardiomyopathy, according to results from a study supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.

26 Jul 2011

Symposium papers highlight role of oxidative stress in cardiovascular disease

Recent years have seen major advances in understanding of the health effects of oxidative stress—including its potential to cause injury to the cardiovascular system. A series of expert updates on the role of oxidative stress in heart failure, atherosclerosis, and other cardiovascular diseases appears in a special symposium in the August issue of The American Journal of the Medical Sciences, official journal of the Southern Society for Clinical Investigation.

26 Jul 2011

Sunshine Heart to sell 115 million shares of common stock in private placement

Sunshine Heart, Inc., today announced it has entered into definitive agreements with new and existing institutional investors in the United States and Canada to sell approximately 115 million shares of common stock in a private placement.

25 Jul 2011

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its supplemental Biologics License Application (sBLA) for SIMPONI.

25 Jul 2011

Rats, fish oil and beetroot juice could lead to health breakthroughs for aging populations

Though rats, fish oil and beetroot juice read like ingredients in a witch's brew, to a Kansas State University research team, information from this combination could lead to health breakthroughs for aging populations and people suffering from heart failure and diabetes.

22 Jul 2011

Anesthesia-associated mortality rises again

In pure numerical terms, anesthesia-associated mortality has risen again. The reasons for this are the disproportionate increase in the numbers of older and multimorbid patients and surgical procedures that would have been unthinkable in the past.

22 Jul 2011

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Canadians newly diagnosed with a life-threatening blood cancer, chronic myeloid leukemia (CML) in chronic phase, now have a new treatment option available to them. Health Canada has granted a notice of compliance with conditions for SPRYCEL (dasatinib) as first-line treatment in patients with chronic phase CML.

22 Jul 2011

Montifiore's surgeons receive certification training for implanting total artificial heart

A surgical team from the Montefiore Einstein Center for Heart and Vascular Care recently received certification training for implanting the SynCardia Total Artificial Heart, a replacement heart implanted in patients at risk of imminent death from heart failure.

22 Jul 2011

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.

22 Jul 2011

Galectin, University of Michigan enter collaboration to study role of Galectins in cardiovascular disease

Galectin Therapeutics Inc. today announced that it has entered into a research collaboration with Dr. Jose Jalife of the University of Michigan Medical School to better understand the relationship of Galectin-3 to cardiac fibrosis in chronic cardiac arrhythmias.

21 Jul 2011

Identification of third microRNA target triggers milestone payment from GSK to Regulus

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has identified a third microRNA target in its alliance with GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK.

21 Jul 2011

AMAG enters definitive merger agreement with Allos Therapeutics

AMAG Pharmaceuticals, Inc. and Allos Therapeutics, Inc. today announced that they have entered into a definitive merger agreement under which the companies will combine in an all-stock merger with a total equity value of approximately $686 million.

21 Jul 2011

US FDA advisory panel votes yes for Edwards heart valve

An U.S. Food and Drug Administration advisory panel met Wednesday to discuss the approval of Edwards Lifesciences Corp's heart valve for patients deemed too sick to have open-heart surgery. The panel voted 9-0 with one abstention in favor of valve.

20 Jul 2011

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the submission of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration for VELCADE® (bortezomib) for injection to add overall survival data after a five-year follow up to the product label.

20 Jul 2011

Two existing clinical stage clients expand development activities with Progenitor Cell Therapy

Progenitor Cell Therapy (PCT), an internationally recognized cell therapy services and development company, and a wholly-owned subsidiary of NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that two existing clinical stage biopharmaceutical corporate clients have chosen to expand their development activities with PCT.

18 Jul 2011

Heart Failure News and Research

Further Reading

Merck secures worldwide rights to vernakalant i.v.

Special panel votes in favor of HDE approval for EXCOR Pediatric VAD

Health Canada issues notice of compliance for OCPI's SAMSCA to treat hyponatremia

Hormone therapy may be hazardous in men with pre-existing heart conditions

Volunteers needed in worldwide study to help people breathe easier

Key risk factors for death, transplantation in children with dilated cardiomyopathy

Symposium papers highlight role of oxidative stress in cardiovascular disease

Sunshine Heart to sell 115 million shares of common stock in private placement

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Rats, fish oil and beetroot juice could lead to health breakthroughs for aging populations

Anesthesia-associated mortality rises again

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Montifiore's surgeons receive certification training for implanting total artificial heart

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Galectin, University of Michigan enter collaboration to study role of Galectins in cardiovascular disease

Identification of third microRNA target triggers milestone payment from GSK to Regulus

AMAG enters definitive merger agreement with Allos Therapeutics

US FDA advisory panel votes yes for Edwards heart valve

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Two existing clinical stage clients expand development activities with Progenitor Cell Therapy

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News